EGFR and non-small cell lung carcinoma: Dividing the EGFR-mutant NSCLC patients into two subpopulations based on YAP1 expression, we found that patients with YAP1_High tumor had immunosuppressive immune cells and inferior prognosis in EGFR-mutant NSCLC patients compared to those with YAP1_Low tumor.